Product Pathways
BCP0010 ABT-263(Navitoclax)
ABT-263 (Navitoclax) is a potent orally bioavailable SMI that is structurally related to ABT-737. ABT-263 disrupts Bcl-2 - Bcl-XL interactions with pro-apoptotic proteins .
BCP0011 ABT737
ABT737,a selective inhibitor of BCL-2, in small cell lung cancer.
BCP0059 HA14-1
Cell-permeable inhibitor of Bcl-2 protein (IC50 ~ 9 µM).
BCP0083 Obatoclax Mesylate
Obatoclax (GX15-070) is an inhibitor of Bcl-2 with Ki of 0.22 μM.
BCP0128 TW-37
TW-37 binds to the BH3 binding groove in Bcl-2 protein competing with BH3 peptides derived from Bid, Bim, and Bad proteins.
BCP0141 YM155
YM155, a novel small molecule survivin inhibitor.
BCP0179 Deguelin
Anticancer and antiviral agent; chemopreventive and pro-apoptotic. Inhibits phorbol ester-induced ornithine decarboxylase and NADH:ubiquinone oxidoreductase activities (IC50 values are 11 and 6.9 nM respectively).
BCP0190 Triptolide(PG490)
Inhibits cytokine-induced gene expression via inhibition of NF-κB transcriptional activity.
BCP0433 JNJ 26854165
JNJ 26854165 (Serdemetan) is an orally bioavailable HDM2 antagonist.
BCP0464 Contusugene ladenovec
Contusugene ladenovec (INGN-201, Ad5CMV-p53, Advexin�) is a replication-impaired adenoviral vector that encodes a wild-type TP53 gene driven by a cytomegalovirus promoter.
第一页 1 2 3 4 最后页 
Only for research purpose , not for human consumption Copyright©2012 ShangHai Biochempartner Co.,Ltd.